scholarly journals Comparative Hypoglycaemic Activity of Fixed Dose Combination Anti-Diabetic Formulations Versus Respective Monotherapies in Diabetic Rabbits

2020 ◽  
Vol 11 (03) ◽  
pp. 409-416
Author(s):  
Rajarao Chinta ◽  
Rohini Pilli
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fasting Blood Glucose ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Fasting Blood Glucose Level ◽  
Hypoglycaemic Activity ◽  
Dose Combination

Type 2 diabetes mellitus is a disease of impaired glucose homeostasis and chronic hyperglycemia. Current approaches for the treatment frequently involving the use of combination therapy. The aim of the present study was to evaluate and compare the hypoglycaemic activity of fixed-dose combination anti-diabetic formulations and respective individual agents using rabbits as an animal model. Experimental diabetes was induced by a single intravenous injection of alloxan monohydrate at a dose of 150 mg/kg. Individual drugs and combination tablets were administered to experimental groups. Fasting blood glucose level was estimated at 0, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours using glucometer. Data were statistically analyzed using student t-test and p less than 0.05 considered as statistically significant. The reduction in fasting blood glucose level in diabetes-induced rabbits was significantly higher with combination products compared to individual drugs. Fixed-dose combination products had shown improved glycaemic control than individual agents. Fixed-dose combination therapy can be used as a suitable option for selected patients requiring multiple glucose-lowering therapies for use as an adjunct to diet and exercise to improve glycaemic control in type 2 diabetes mellitus.

135-OR: The Effect of Fixed-Dose Combination of Insulin Degludec and Liraglutide on Serum Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 135-OR
Author(s):  
ELENI PAPPA ◽  
CHRISTINA KOSTARA ◽  
CONSTANTINOS TELLIS ◽  
ALEXANDROS D. TSELEPIS ◽  
ELENI BAIRAKTARI ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipoprotein Metabolism ◽  
Serum Lipoprotein ◽  
Insulin Degludec ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination

Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus

Therapy ◽  
2006 ◽  
Vol 3 (5) ◽  
pp. 559-569
Author(s):  
Giuseppe Derosa ◽  
Sibilla AT Salvadeo ◽  
Arrigo FG Cicero
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination

scholarly journals Assessment of Clinical Experience of Triple Drug Fixed-dose Combination of Glimepiride, Metformin and Voglibose in the Management of Type 2 Diabetes Mellitus: A Retrospective Study

2021 ◽  
Author(s):  
Ganapathi Bantwal ◽  
Vageesh Ayyar ◽  
Rajiv Kovil ◽  
Manoj Chawla ◽  
Tejas Shah ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Antidiabetic Therapy ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Dose Combination ◽  
The Mean

Introduction: Poor adherence of patients to the polypharmacy approach is a crucial challenge in the management of Type 2 Diabetes Mellitus (T2DM) and use of triple Fixed-Dose Combination (FDC) of metformin, glimepiride, and voglibose is effective in achieving glycaemic control and would aid in improved drug adherence. Aim: To analyse clinical profile and treatment patterns of FDC of glimepiride, metformin, and voglibose with or without other antidiabetic therapy in patients with T2DM. Materials and Methods: A retrospective, observational, multi- centric study conducted during August 2019 to March 2020. Included patients of either sex, ≥18 years of age with T2DM and who had received treatment with FDC of glimepiride, metformin, and voglibose of varying strengths with or without other antidiabetic therapy. Data extracted from medical records included demographic characteristics, duration of disease, co- morbidities, concomitant medications and dosage pattern. Data were analysed using Chi-square test and Mann-Whitney U test. Results: A total of 2650 patients with T2DM were included, of which 1689 (63.7%) were males. The mean (standard deviation {SD}) age was 54.2 (11.4) years. The average Body Mass Index (BMI) was 27.2 (4.3) kg/m2 and hypertension 1656 (62.5%) and dyslipidaemia 1109 (41.9%) were the most common co-morbidities. Dipeptidyl peptidase-4 inhibitors 908 (34.3%) and antihypertensives 1601 (60.4%) were the most common concomitant diabetic and non diabetic medications received, respectively. Glimepiride (2 mg)+metformin (500 mg)+voglibose (0.2 mg) FDC twice-a-day 878 (33.1%) was a common triple FDC. A total of 2449 (92.4%) patients were compliant and 2585 (97.9%) achieved glycaemic goal with triple FDC treatment. During the therapy, the majority of patients had decreased weight 1106 (67.2%). The mean Haemoglobin A1c (HbA1c) levels significantly decreased post-treatment (mean change 1.45%; p-value <0.001). Family history of diabetes mellitus, obesity, sedentary lifestyle were the most common risk factors and smoking being prevalent in males. Conclusion: Overall results demonstrate that triple FDC of glimepiride, metformin, and voglibose was effective in reducing HbA1c and weight and was well tolerated. Also, it improves compliance in Indian patients with T2DM.

Sign in / Sign up

Export Citation Format

Share Document